157 related articles for article (PubMed ID: 29807243)
1. Combination of 7-hydroxycoumarin in a platinum(IV) complex derived from cisplatin enhanced cytotoxicity with multiple mechanisms of action.
Hua W; Zhao J; Hu W; Gou S
J Inorg Biochem; 2018 Sep; 186():17-23. PubMed ID: 29807243
[TBL] [Abstract][Full Text] [Related]
2. Construction of Dual Stimuli-Responsive Platinum(IV) Hybrids with NQO1 Targeting Ability and Overcoming Cisplatin Resistance.
Fang L; Qin X; Zhao J; Gou S
Inorg Chem; 2019 Feb; 58(3):2191-2200. PubMed ID: 30657321
[TBL] [Abstract][Full Text] [Related]
3. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
Chen F; Qin X; Xu G; Gou S; Jin X
Biochem Pharmacol; 2017 Jul; 135():50-68. PubMed ID: 28288821
[TBL] [Abstract][Full Text] [Related]
4. Antitumor platinum(II) complexes of N-monoalkyl-1R, 2R-diaminocyclohexane derivatives with alkyl groups as hindrance.
Sun Y; Yin R; Gou S; Zhaojian
J Inorg Biochem; 2012 Jul; 112():68-76. PubMed ID: 22561544
[TBL] [Abstract][Full Text] [Related]
5. Novel Pt(IV) complexes containing salvigenin ligand reverse cisplatin-induced resistance by inhibiting Rap1b-mediated cancer cell stemness in esophageal squamous cell carcinoma treatments.
Zhao J; Wu K; Yang Y; Liu D; Zhang C; Li X
Bioorg Chem; 2024 Jun; 147():107384. PubMed ID: 38643568
[TBL] [Abstract][Full Text] [Related]
6. A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response.
Chen F; Huang X; Wu M; Gou S; Hu W
Cancer Lett; 2017 Jan; 385():168-178. PubMed ID: 27793693
[TBL] [Abstract][Full Text] [Related]
7. Antitumor and cellular pharmacological properties of a novel platinum(IV) complex: trans-[PtCl(2)(OH)(2)(dimethylamine) (isopropylamine)].
Pérez JM; Kelland LR; Montero EI; Boxall FE; Fuertes MA; Alonso C; Navarro-Ranninger C
Mol Pharmacol; 2003 Apr; 63(4):933-44. PubMed ID: 12644595
[TBL] [Abstract][Full Text] [Related]
8. Platinum(IV) complexes conjugated with chalcone analogs as dual targeting anticancer agents: In vitro and in vivo studies.
Huang X; Liu Z; Wang M; Yin X; Wang Y; Dai L; Wang H
Bioorg Chem; 2020 Dec; 105():104430. PubMed ID: 33171407
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of a novel series of glycosylated platinum(iv) complexes as antitumor agents.
Wang Q; Huang Z; Ma J; Lu X; Zhang L; Wang X; George Wang P
Dalton Trans; 2016 Jun; 45(25):10366-74. PubMed ID: 27252024
[TBL] [Abstract][Full Text] [Related]
10. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of antitumor azolato-bridged dinuclear platinum(ii) complexes with in vivo antitumor efficacy and unique in vitro cytotoxicity profiles.
Komeda S; Takayama H; Suzuki T; Odani A; Yamori T; Chikuma M
Metallomics; 2013 May; 5(5):461-8. PubMed ID: 23608770
[TBL] [Abstract][Full Text] [Related]
12. Naproxen platinum(iv) hybrids inhibiting cycloxygenases and matrix metalloproteinases and causing DNA damage: synthesis and biological evaluation as antitumor agents in vitro and in vivo.
Chen Y; Wang Q; Li Z; Liu Z; Zhao Y; Zhang J; Liu M; Wang Z; Li D; Han J
Dalton Trans; 2020 Apr; 49(16):5192-5204. PubMed ID: 32236281
[TBL] [Abstract][Full Text] [Related]
13. Conjugation of platinum(IV) complexes with chlorambucil to overcome cisplatin resistance via a "joint action" mode toward DNA.
Qin X; Fang L; Chen F; Gou S
Eur J Med Chem; 2017 Sep; 137():167-175. PubMed ID: 28586717
[TBL] [Abstract][Full Text] [Related]
14. Glycyrrhetinic Acid as a Hepatocyte Targeting Ligand-Functionalized Platinum(IV) Complexes for Hepatocellular Carcinoma Therapy and Overcoming Multidrug Resistance.
Huang X; Li G; Li H; Zhong W; Jiang G; Cai J; Xiong Q; Wu C; Su K; Huang R; Xu S; Liu Z; Wang M; Wang H
J Med Chem; 2024 May; 67(10):8020-8042. PubMed ID: 38727048
[TBL] [Abstract][Full Text] [Related]
15. Mono-functionalized glycosylated platinum(IV) complexes possessed both pH and redox dual-responsive properties: Exhibited enhanced safety and preferentially accumulated in cancer cells in vitro and in vivo.
Ma J; Yang X; Hao W; Huang Z; Wang X; Wang PG
Eur J Med Chem; 2017 Mar; 128():45-55. PubMed ID: 28147308
[TBL] [Abstract][Full Text] [Related]
16. Toward overcoming cisplatin resistance via sterically hindered platinum(II) complexes.
Yu H; Gou S; Wang Z; Chen F; Fang L
Eur J Med Chem; 2016 May; 114():141-52. PubMed ID: 26974381
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of bi-functional 7-hydroxycoumarin platinum(IV) complexes as antitumor agents.
Wang Q; Chen Y; Li G; Liu Z; Ma J; Liu M; Li D; Han J; Wang B
Bioorg Med Chem; 2019 May; 27(10):2112-2121. PubMed ID: 30981607
[TBL] [Abstract][Full Text] [Related]
18. Cellular and biomolecular responses of human ovarian cancer cells to cytostatic dinuclear platinum(II) complexes.
Lin M; Wang X; Zhu J; Fan D; Zhang Y; Zhang J; Guo Z
Apoptosis; 2011 Mar; 16(3):288-300. PubMed ID: 21107699
[TBL] [Abstract][Full Text] [Related]
19. Antitumour and antiangiogenic activities of [Pt(O,O'-acac)(γ-acac)(DMS)] in a xenograft model of human renal cell carcinoma.
Muscella A; Vetrugno C; Biagioni F; Calabriso N; Calierno MT; Fornai F; De Pascali SA; Marsigliante S; Fanizzi FP
Br J Pharmacol; 2016 Sep; 173(17):2633-44. PubMed ID: 27351124
[TBL] [Abstract][Full Text] [Related]
20. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance.
Huang X; Wang M; Wang C; Hu W; You Q; Yang Y; Yu C; Liao Z; Gou S; Wang H
Bioorg Chem; 2019 Nov; 92():103236. PubMed ID: 31494328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
